Compare Abbott Laboratories (ABT) vs YieldMax AMZN Option Income Strategy ETF (AMZY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Abbott Laboratories vs YieldMax AMZN Option Income Strategy ETF — how do they compare? Abbott Laboratories trades at $111.3 (market cap $191.92B), while YieldMax AMZN Option Income Strategy ETF trades at $11.04. The key difference: Abbott Laboratories pays a 2.27% dividend while YieldMax AMZN Option Income Strategy ETF pays none, and Abbott Laboratories is trading nearer its 52-week high, YieldMax AMZN Option Income Strategy ETF nearer its low. Which is the better fit depends on your goals.
| ABT | AMZY | |
|---|---|---|
Market Cap | $191.92B | — |
Sector | Health | Income / Options Overlay |
52-Week High | $136.62 | $15.75 |
52-Week Low | $82.57 | $9.98 |
Enterprise Value | $218.92B | — |
Dividend Yield | 2.27% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $111.27, up 1.39% on the day, with strong analyst support (76% buy ratings) and a consensus price target of $120.70. The stock shows bullish technical momentum with recent earnings beats in Q1 and Q2 2026, though Q4 2025 missed expectations. Revenue growth remains steady at $44.33B for 2025, with solid profitability metrics including 56.61% gross margin and 11.65% net income margin. Recent corporate developments include CE Mark approval for innovative dual glucose-ketone sensors and positive ACS guideline updates for Cologuard cancer screening.
The outlook remains positive with Wall Street consensus favoring accumulation, though risks include potential earnings volatility and competitive pressures in medical technology. The current valuation at 35.89 P/E appears reasonable given the company's innovation pipeline and market leadership. Upside potential exists toward the $120-134 analyst target range, supported by strong cash flow generation and dividend stability.
AMZY trades at $11.24, down 1.83% in the past 24 hours. The ETF exhibits a bullish technical signal overall, with strong directional movement indicators (ADX) signaling buy conditions, while oscillators remain neutral. Recent news highlights consistent weekly dividend distributions, but financial ratios are unavailable, limiting fundamental clarity.
The outlook is mixed: high dividend yield appeals to income seekers, but analyst reports warn of inevitable NAV erosion and amplified downside risk. Sentiment is cautious due to concerns over sustainable payouts and long-term underperformance versus Amazon. Investors face trade-offs between income generation and capital preservation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About YieldMax AMZN Option Income Strategy ETF
AMZY is an actively managed ETF that seeks to generate monthly income by selling call options on Amazon (AMZN) stock. It aims to provide high yield while maintaining exposure to the price movements of the e-commerce giant.
Read more on AMZY →
